Literature DB >> 20393456

Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers.

Nadine Petrovsky1, Boris B Quednow, Ulrich Ettinger, Anne Schmechtig, Rainald Mössner, David A Collier, Kai-Uwe Kühn, Wolfgang Maier, Michael Wagner, Veena Kumari.   

Abstract

Attentional gating deficits, commonly measured by prepulse inhibition (PPI) of the acoustic startle response (ASR), have been established as an endophenotype of schizophrenia. Prepulse inhibition is heritable and has been associated with polymorphisms in serotonin and dopamine system genes. Prepulse inhibition can be enhanced by nicotine, and therefore it has been proposed that schizophrenia patients smoke to ameliorate their early attentional deficits. The PPI-enhancing effects of nicotine in rodents are strain dependent, suggesting a genetic contribution to PPI within the nicotinic acetylcholine receptor (nAChR) system. Recent human genetic studies also imply that tobacco dependence is affected by polymorphisms in the alpha3/alpha5 subunits of the nAChR (CHRNA3/CHRNA5) gene cluster. We, therefore, investigated the impact of two common CHRNA3 polymorphisms (rs1051730/rs1317286) on PPI, startle reactivity, and habituation of the ASR in two independent samples of 107 healthy British volunteers and 73 schizophrenia patients hailing from Germany. In both samples, PPI was influenced by both CHRNA3 polymorphisms (combined p-value=0.0027), which were strongly linked. Moreover, CHRNA3 genotype was associated with chronicity, treatment, and negative symptoms in the schizophrenia sample. These results suggest that sensorimotor gating is influenced by variations of the CHRNA3 gene, which might also have an impact on the course and severity of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393456      PMCID: PMC3055462          DOI: 10.1038/npp.2010.12

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  77 in total

1.  Effects of smoking on acoustic startle and prepulse inhibition in humans.

Authors:  E Duncan; S Madonick; S Chakravorty; A Parwani; S Szilagyi; T Efferen; S Gonzenbach; B Angrist; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

2.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 3.  Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges.

Authors:  N R Swerdlow; M A Geyer; D L Braff
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 4.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

5.  Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice.

Authors:  Rudy Schreiber; Marion Dalmus; Jean De Vry
Journal:  Psychopharmacology (Berl)       Date:  2001-10-19       Impact factor: 4.530

6.  Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia.

Authors:  Katja Ludewig; Mark A Geyer; Franz X Vollenweider
Journal:  Biol Psychiatry       Date:  2003-07-15       Impact factor: 13.382

7.  Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: relevance to smoking in schizophrenia patients.

Authors:  Cecile Spielewoy; Athina Markou
Journal:  Behav Genet       Date:  2004-05       Impact factor: 2.805

8.  Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission.

Authors:  William Perry; David Feifel; Arpi Minassian; Indira Bhattacharjie; David L Braff
Journal:  Am J Psychiatry       Date:  2002-08       Impact factor: 18.112

9.  Genetic influences on prepulse inhibition of startle reflex in humans.

Authors:  Andrey P Anokhin; Andrew C Heath; Erin Myers; Angela Ralano; Suzanne Wood
Journal:  Neurosci Lett       Date:  2003-12-15       Impact factor: 3.046

10.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.

Authors:  Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  34 in total

Review 1.  Impact of TCF4 on the genetics of schizophrenia.

Authors:  Leonhard Lennertz; Boris B Quednow; Jens Benninghoff; Michael Wagner; Wolfgang Maier; Rainald Mössner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-09-20       Impact factor: 5.270

Review 2.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

3.  CHRFAM7A gene expression in schizophrenia: clinical correlates and the effect of antipsychotic treatment.

Authors:  Sunil V Kalmady; Rimjhim Agrawal; Deepthi Venugopal; Venkataram Shivakumar; Anekal C Amaresha; Sri Mahavir Agarwal; Manjula Subbanna; Ashwini Rajasekaran; Janardhanan C Narayanaswamy; Monojit Debnath; Ganesan Venkatasubramanian
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

4.  Effects of intravenous nicotine on prepulse inhibition in smokers and non-smokers: relationship with familial smoking.

Authors:  David J Drobes; David A MacQueen; Melissa D Blank; Michael E Saladin; Robert J Malcolm
Journal:  Psychopharmacology (Berl)       Date:  2013-04-28       Impact factor: 4.530

5.  Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine.

Authors:  Osamu Uchiumi; Yoshiyuki Kasahara; Asami Fukui; F Scott Hall; George R Uhl; Ichiro Sora
Journal:  Neuropharmacology       Date:  2012-07-15       Impact factor: 5.250

Review 6.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

Review 7.  Endophenotype best practices.

Authors:  William G Iacono; Stephen M Malone; Scott I Vrieze
Journal:  Int J Psychophysiol       Date:  2016-07-27       Impact factor: 2.997

8.  Genetics and smoking.

Authors:  Anu Loukola; Jenni Hällfors; Tellervo Korhonen; Jaakko Kaprio
Journal:  Curr Addict Rep       Date:  2014-03-01

Review 9.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

10.  Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.

Authors:  Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.